TSS
ALNY icon

Two Sigma Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

Two Sigma Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,400
Closed -$935K – 1637
2024
Q3 		$935K Sell
3,400
-20,400
-86% -$5.31M 0.02% 914
2024
Q2 		$5.78M Buy
23,800
+18,000
+310% +$2.84M 0.07% 316
2024
Q1 		$867K Sell
5,800
-8,400
-59% -$1.4M 0.01% 1222
2023
Q4 		$2.72M Buy
14,200
+11,100
+358% +$1.89M 0.03% 575
2023
Q3 		$549K Buy
+3,100
New +$591K 0.01% 1464
2022
Q2 		– Sell
-2,000
Closed -$327K – 2183
2022
Q1 		$327K Buy
+2,000
New +$305K 0.01% 1332
2020
Q2 		– Sell
-4,700
Closed -$512K – 1350
2020
Q1 		$512K Buy
4,700
+900
+24% +$104K 0.01% 614
2019
Q4 		$438K Buy
+3,800
New +$379K ﹤0.01% 1531
2018
Q3 		– Sell
-2,400
Closed -$236K – 2543
2018
Q2 		$236K Sell
2,400
-10,800
-82% -$1.07M ﹤0.01% 2233
2018
Q1 		$1.57M Buy
+13,200
New +$1.7M 0.01% 1018

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Two Sigma Securities's ALNY Position: Q4 2025 in Review

Two Sigma Securities sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 1,740 shares — an estimated $793K sold.

Two Sigma Securities first reported a position in ALNY in Q2 2017 and held it in 16 quarters. The position peaked at $13.2M in Q2 2024. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Two Sigma Securities reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Securities sold 1,740 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $793K.
  • Two Sigma Securities first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 16 quarters.
  • Two Sigma Securities's Alnylam Pharmaceuticals position peaked at $13.2M in Q2 2024.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.